Myriad Builds Case For Personalized Rheumatoid Arthritis Drugs
This article was originally published in The Gray Sheet
Data presented at the American College of Rheumatology meeting show that not everybody needs a biologic, and that biomarker testing could enable more cost-effective use, says Myriad subsidiary Crescendo.
You may also be interested in...
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, is talking-up the results of four different clinical trials of its Vectra DA multi-analyte blood test for rheumatoid arthritis that were presented at this year's American College of Rheumatology meeting in Washington, DC.
Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.
US FDA’ s latest ‘n of 1’ guidance describes clinical considerations for INDs to support dosing and monitoring of an individual with a life-threatening genetic disease who is eligible to receive an ASO; recommendations apply only when a few patients may be candidates for treatment.